Opticyte Revenue and Competitors
Estimated Revenue & Valuation
- Opticyte's estimated annual revenue is currently $1.3M per year.
- Opticyte's estimated revenue per employee is $125,500
- Opticyte's total funding is $5.7M.
Employee Data
- Opticyte has 10 Employees.
- Opticyte grew their employee count by 43% last year.
Opticyte's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Clinical Affairs | Reveal Email/Phone |
Opticyte Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.9M | 39 | 117% | $14.9M | N/A |
#2 | $44.9M | 143 | -30% | $211.3M | N/A |
#3 | $54M | 172 | 11% | $35.5M | N/A |
#4 | $4.3M | 17 | -19% | N/A | N/A |
#5 | $18.3M | 73 | N/A | N/A | N/A |
#6 | $8.3M | 33 | 6% | N/A | N/A |
#7 | $81.1M | 323 | 17% | N/A | N/A |
#8 | $7M | 28 | -12% | N/A | N/A |
#9 | $204.8M | 816 | 3% | N/A | N/A |
#10 | $6.3M | 50 | 25% | $27.5M | N/A |
What Is Opticyte?
At Opticyte, we are committed to transforming the standard of care for the leading causes of organ failure, including sepsis. The problem is massive, is expensive to treat, and leads to one death every 2.8 seconds globally. Current technologies including pulse oximeters fail to provide clinicians with the definitive data they need to diagnose, monitor, and treat patients in real-time, when they have the best chance of preventing organ failure. Opticyte's Cell O2 Monitor is the first and only single solution to provide definitive, continuous, and actionable insights for this critical unmet need. Opticyte's executive and advisory team includes pioneers in new optical spectroscopy and multivariate analysis technology, leaders in medical device commercialization, and medical clinicians. The company’s early funding successes, research validation, and product development milestones provide credibility and reinforce our position as a disruptive medical device innovator.
keywords:N/A$5.7M
Total Funding
10
Number of Employees
$1.3M
Revenue (est)
43%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Opticyte News
Merakris Therapeutics, Inc. RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2M | 10 | 0% | N/A |
#2 | $1.5M | 10 | -89% | N/A |
#3 | $17.5M | 10 | -33% | $221M |
#4 | $0.9M | 10 | N/A | N/A |
#5 | $0.9M | 10 | N/A | N/A |